Suman Rao

Harvard Medical School/Dana-Farber Cancer Institute, Boston, MA, United States 
Cancer Biology
"Suman Rao"
Mean distance: (not calculated yet)
BETA: Related publications


You can help our author matching system! If you notice any publications incorrectly attributed to this author, please sign in and mark matches as correct or incorrect.

Rao S, Thibault B, Peyrard L, et al. (2021) Quantitative Analysis of the Potency of Equimolar Two-Drug Combinations and Combi-Molecules Involving Kinase Inhibitors In Vitro: The Concept of Balanced Targeting. International Journal of Molecular Sciences. 22
Gurbani D, Du G, Henning NJ, et al. (2020) Structure and Characterization of a Covalent Inhibitor of Src Kinase. Frontiers in Molecular Biosciences. 7: 81
Du G, Rao S, Gurbani D, et al. (2020) Structure-based design of a potent and selective covalent inhibitor for SRC kinase that targets a p-Loop cysteine. Journal of Medicinal Chemistry
Rao S, Gurbani D, Du G, et al. (2019) Leveraging Compound Promiscuity to Identify Targetable Cysteines within the Kinome. Cell Chemical Biology
Rao S, Du G, Hafner M, et al. (2019) A multi-targeted probe-based strategy to identify signaling vulnerabilities in cancers. The Journal of Biological Chemistry
Rao S, Li T, Everley R, et al. (2017) Abstract 1222: Developing kinase inhibitors with polypharmacological profiles for the treatment of resistant cancers Cancer Research. 77: 1222-1222
Tan L, Gurbani D, Weisberg EL, et al. (2016) Studies of TAK1-centered polypharmacology with novel covalent TAK1 inhibitors. Bioorganic & Medicinal Chemistry
Tan L, Gurbani D, Weisberg EL, et al. (2016) Structure-guided development of covalent TAK1 inhibitors. Bioorganic & Medicinal Chemistry
Rao S, Larroque-Lombard AL, Peyrard L, et al. (2015) Target modulation by a kinase inhibitor engineered to induce a tandem blockade of the epidermal growth factor receptor (EGFR) and c-Src: the concept of type III combi-targeting. Plos One. 10: e0117215
Rao S, Larroque-Lombard A, Allal B, et al. (2015) Abstract 727: Signaling redundancy between EGFR and c-Met: molecular analysis of concurrent inhibition of c-Src and therapeutic potential against prostate cancer Cancer Research. 75: 727-727
See more...